<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03973814</url>
  </required_header>
  <id_info>
    <org_study_id>BxIIRgrant</org_study_id>
    <nct_id>NCT03973814</nct_id>
  </id_info>
  <brief_title>Hypothermia Risk With Continuous Renal Replacement Therapy</brief_title>
  <acronym>HR-CRRT</acronym>
  <official_title>Hypothermia Risk With Continuous Renal Replacement Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Karolinska University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Skane University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The present study aims at testing if the TherMax blood warmer is more accurate and reliable
      in reaching and maintaining chosen target temperature during continuous renal replacement
      therapy as compared to the Prismaflo IIS blood warmer used for the PrismaFlex system.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Blood warming devices during continuous renal replacement therapy (CRRT) have not been
      adequately tested.

      The novel TherMax blood warmer for the newly introduced PrisMax System heats blood and
      replacement solutions via a dry heat plate system. In contrast, the PRISMAFLO IIS Blood
      Warmer for PRISMAFLEX System uses an electric heating sleeve on a standard CRRT filter set.

      Data on adverse events (AE) during continuous renal replacement therapy (CRRT) has been
      studied and one of the most common AE was hypothermia, reported in 44% of all cases.

      The present study aims at testing if the TherMax blood warmer is more accurate and reliable
      in reaching and maintaining chosen target temperature during CRRT as compared to the blood
      warmer used for the PrismaFlex system.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The investigators will assess body temperature before-, during- and after Thermax blood warming treatment. Patients are essentially their own controls.
Moreover, we will use historic data on the previous blood warmer for the Prismaflex device to assess temperature changes.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Temperature, accuracy</measure>
    <time_frame>24 hours</time_frame>
    <description>During use of Thermax; hourly difference between prescribed temperature-measured temperature; accuracy 0,1 Celsius</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Temperature, differences</measure>
    <time_frame>12-18 hours (six hour warming period)</time_frame>
    <description>Difference to 36.5 Celsius, std deviation, interquartile range: Prior to Thermax, during Thermax and after Thermax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Historic comparator</measure>
    <time_frame>24 hours</time_frame>
    <description>Using registry/PDMS data, how did the old blood warmer perform with regards to temperature</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Acute Kidney Injury</condition>
  <condition>Hypothermia</condition>
  <arm_group>
    <arm_group_label>Prior to Thermax Warming</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Baseline temperature</description>
  </arm_group>
  <arm_group>
    <arm_group_label>During warming</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temperature during Thermax warming</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post warming</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Temperature after cessation of Thermax warming</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Thermax Blood Warmer</intervention_name>
    <description>Patients will be their own controls: Prior to-, during-, and after Thermax blood warming.</description>
    <arm_group_label>During warming</arm_group_label>
    <arm_group_label>Post warming</arm_group_label>
    <arm_group_label>Prior to Thermax Warming</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult (18-100 years) critically ill patients treated with CRRT.

        Exclusion Criteria:

          -  Patients under 18 years of age. Non-RRT patients.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Max Bell, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marcus Broman, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Max Bell, MD, PhD</last_name>
    <phone>+46708278533</phone>
    <email>max.bell@sll.se</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marcus Broman, MD, PhD</last_name>
    <phone>+46702898425</phone>
    <email>ewert.broman@icloud.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>17176</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>May 30, 2019</study_first_submitted>
  <study_first_submitted_qc>May 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2019</study_first_posted>
  <last_update_submitted>February 19, 2020</last_update_submitted>
  <last_update_submitted_qc>February 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Max Bell</investigator_full_name>
    <investigator_title>MD, PhD, Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>continuous renal replacement therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Kidney Injury</mesh_term>
    <mesh_term>Hypothermia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified patient and machine data may be made available after study completion, but this depends on the patent holder.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Six months after study completion</ipd_time_frame>
    <ipd_access_criteria>Data access will be reviewed by the PI:s and research group.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

